The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1621
April 5, 2021
View Complete Issue         Table of Contents 2019 
Semaglutide (Ozempic) for Weight Loss
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Semaglutide (Ozempic) for Weight Loss
April 5, 2021 (Issue: 1621)
In recently published clinical trials, once-weekly subcutaneous injection of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of type 2 diabetes and to reduce the risk...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Semaglutide (Ozempic) for Weight Loss
Article code: 1621c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.